Published on January 20, 2014

There is no end to troubles faced by Ranbaxy, issues with USFDA are not in a mood to settle down. In a fresh incidence USFDA has red flagged Ranbaxys fourth plant. Company has raised concerns at the company’s quality and manufacturing standard at Toansa (Punjab). The USFDA issued a form 483 after having a complete inspection at the plant. All the facilities provided by the company from this plant are under USFDA scanner and has raised the questions on the efforts made by the country to improve its quality standard. Already three plants of the company are under USFDA scanner. Ranbaxy confirmed about this form and has affirmed that company will follow procedure to sort out the matter as soon as possible.

Recently annual convention of All India Organization of Chemists and druggists was held. The druggist association has requested the central government to enforce strict control on drugs for terminal diseases such as cancer and kidney ailments. Association is unhappy with the new policy o 100% FDI which is again promoted by government. According to them if this policy is executed it will immediately have an adverse impact on the variety of generic drugs. Pharmacists will fill up their store with foreign drugs and the economical drugs will get no place in the market.

In a recent move Glaxosmithkline has joined the Torrent pharma and Cipla to restore the margins payable to dealers and retailers. Company has decided to offer the 10% to wholesalers and 20% to retailers. These companies have decided to go against DPCO order announced in May 2013.